IP Verse

Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure

Patent No. EP4212152 (titled "Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure") was filed by Novartis on May 9, 2016. The application was issued on Apr 30, 2025.

Patent Summary

A dosage regimen for the treatment of chronic systolic heart failure with reduced ejection fraction in a human patient. The regimen involves initiating therapy with a sacubitril and valsartan combination in a 1:1 molar ratio, with the starting dose being 50 mg of sacubitril and valsartan in a 1:1 molar ratio. The therapy is titrated over 12 weeks to achieve and maintain a target dose of 200 mg twice daily. The regimen is further extended to a target dose of 200 mg twice daily after 4 weeks of titration.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
TEVA PHARMACEUTICALSNov 21, 2025D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4212152

NOVARTIS
Application Number
EP23154757A
Filing Date
May 9, 2016
Status
Granted And Under Opposition
Mar 28, 2025
Publication Date
Apr 30, 2025
External Links
Slate, Register , Google Patents